A Phase 1 interventional study of Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg and Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg in Neoplasm, sponsored by Bayer. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-11-18.
Sponsored by Bayer · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Continuous dosing of BAY73-4506 in patients with advanced cancer
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 86 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adequate bone marrow, liver, and renal function as assessed by the following laboratory requirements:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg
Drug: Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg
Drug: Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg
Drug: Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg
Drug: Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg
Drug: HCC Child-Pugh A expansion cohort: Regorafenib 100 mg
Drug: HCC Child-Pugh B expansion cohort: Regorafenib 100 mg
Drug: NSCLC expansion cohort: Regorafenib 100 mg
Participants in the dose-escalation cohort received a single 20 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 20 mg oral co-precipitate (CP) tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
Participants in the dose-escalation cohort received a single 40 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 40 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
Participants in the dose-escalation cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
Participants in the dose-escalation cohort received a single 120 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 120 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
Participants in the dose-escalation cohort received a single 140 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 140 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
Hepatocellular carcinoma (HCC) Participants with Child Pugh A in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
Hepatocellular carcinoma (HCC) Participants with Child Pugh B in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
Non-small cell lung cancer (NSCLC) participants in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
Maximum Tolerated Dose (MTD)
The MTD was defined as the highest dose level, which could be given to 6 participants such that no more than 1 participant (less than 33%) experienced a dose-limiting toxicity (DLT).
Time frame: Within first 4 weeks of treatment
Maximum Observed Plasma Concentration After Single Dose Administration (Cmax)
Cmax refers to the highest measured drug concentration, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.
Time frame: Blood samples were collected on Cycle 1, Day 1. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10, 24, and 48 h post-dose
Area Under the Concentration vs. Time Curve From Zero to Infinity After Single (First) Dose (AUC)
The AUC is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.
Time frame: Blood samples were collected on Cycle 1, Day 1. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10, 24, and 48 h post-dose
Cmax at Steady State During a Dosing Interval (Cmax,ss)
Cmax,ss refers to the highest measured drug concentration, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample, after multiple dose administration and after a steady state concentration has been reached.
Time frame: Blood samples were collected at on Cycle 2, Day 1 and on Cycle 3, Day 1 for expansion cohort. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10 and 24h post-dose.
AUC From Time 0 to 24 Hours at Steady State(AUC(0-24),ss)
AUC(0-24),ss is a measure of systemic drug exposure over 24 hours, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample, after multiple dose administration and after a steady state concentration has been reached.
Time frame: Blood samples were collected on Cycle 2, Day 1 and on Cycle 3, Day 1 for expansion cohort. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10 and 24h post-dose.
AUC From Time 0 to the Last Data Point > Lower Limit of Quantification (LLOQ) (AUC(0-tlast))
The AUC(0-tlast) is a measure of systemic drug exposure from time 0 up to the time point at which the last measurable drug could be detectable, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.
Time frame: Blood samples were collected on Cycle 1, Day 1. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10, 24, and 48 h post-dose
Area Under the Concentration vs. Time Curve From Zero to Infinity After Single (First) Dose Divided by Dose (AUC/D)
The AUC/D is a measure of systemic drug exposure (AUC) after the first single dose, which is then divided by that dose. It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.
Time frame: Blood samples were collected on Cycle 1, Day 1. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10, 24, and 48 h post-dose
Maximum Observed Plasma Concentration After Single Dose Administration Divided by Dose (Cmax/D)
Cmax/D refers to the highest measured drug concentration after a single dose administration, which is then divided by the administered dose. It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.
Time frame: Blood samples were collected on Cycle 1, Day 1. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10, 24, and 48 h post-dose
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Tmax refers to the time after dosing when a drug attains its highest measurable concentration (Cmax). It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.
Time frame: Blood samples were collected on Cycle 1, Day 1. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10, 24, and 48 h post-dose.
Half-life Associated With the Terminal Slope (T1/2)
T1/2 is the period of time required for the concentration or amount of drug in the body to be reduced to exactly one-half of a given concentration or amount. It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.
Time frame: Blood samples were collected on Cycle 1, Day 1. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10, 24, and 48 h post-dose.
Cmax at Steady State During a Dosing Interval Divided by Dose (Cmax,ss/D)
Cmax,ss/D refers to the highest measured drug concentration after multiple dose administration and after a steady state concentration has been reached, which is then divided by the administered dose. It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.
Time frame: Blood samples were collected at on Cycle 2, Day 1 and on Cycle 3, Day 1 for expansion cohort. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10 and 24h post-dose
AUC From Time 0 to 24 Hours at Steady State Divided by Dose (AUC(0-24)ss/D)
AUC(0-24)ss/D is a measure of systemic drug exposure (AUC) over 24 hours after multiple dose administration and after a steady state concentration has been reached, which is then divided by the administered dose. It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.
Time frame: Blood samples were collected on Cycle 2, Day 1 and on Cycle 3, Day 1 for expansion cohort. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10 and 24h post-dose
Time to Reach Maximum Observed Plasma Concentration at Steady State (Tmax,ss)
Tmax,ss refers to the time after multiple dose administration and after a steady state concentration has been reached when a drug attains its highest measurable concentration (Cmax). It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.
Time frame: Blood samples were collected on Cycle 2, Day 1 and on Cycle 3, Day 1 for expansion cohort. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10 and 24h post-dose
Ratio of Cmax,ss/Cmax (RACmax)
RACmax is the ratio of the highest drug concentration at steady state to the highest drug concentration after single dose administration. It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.
Time frame: Blood samples were collected on Cycle 1, Day 1 and Cycle 2, Day 1 and on Cycle 3, Day 1 for expansion cohort. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10 and 24h post-dose
Ratio of Cmin,ss/Cmin (RACmin)
RACmin is the ratio of the lowest drug concentration at steady state to the lowest drug concentration after single dose administration. It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.
Time frame: Blood samples were collected on Cycle 1, Day 1 and Cycle 2, Day 1 and on Cycle 3, Day 1 for expansion cohort. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10 and 24h post-dose
Ratio of AUCt,ss/AUCt (RAAUC)
RAAUC is the ratio of the measure of systemic drug exposure over a specific dosing interval at steady state to the measure of systemic drug exposure over a specific dosing interval after single dose administration. It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.
Time frame: Blood samples were collected on Cycle 1, Day 1 and Cycle 2, Day 1 and on Cycle 3, Day 1 for expansion cohort. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10 and 24h post-dose
Ratio of AUCt,ss/AUC (RLIN)
RLIN is the ratio of the measure of systemic drug exposure at steady state to the measure of systemic drug exposure after single dose administration. It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.
Time frame: Blood samples were collected on Cycle 1, Day 1 and Cycle 2, Day 1. Samples were drawn at the following time points: 0 h pre-dose, 0.5, 1, 2, 4, 8, 10 and 24h post-dose
Biomarker Vascular Endothelial Growth Factor (VEGF) Plasma Levels
The analysis of Biomarker VEGF plasma levels is not done
Time frame: No data obtained
Biomarker Soluble Vascular Endothelial Growth Factor Receptor 2 (sCEGFR-2) Plasma Levels
The analysis of Biomarker sCEGFR-2 plasma levels is not done.
Time frame: No data obtained
Tumor Progression in Dose Escalation Cohort
Tumor progression evaluates changes in a tumor or tumors over time due to worsening of disease. Measurements and observations of the tumor status were performed before, during and after treatment. Progression for solid tumors was evaluated based on the Response Evaluation Criteria in Solid Tumors (RECIST 1.0) criteria. Tumor dimensions were measured in millimeters and the longest diameter (LD) was recorded for up to 5 lesions per organ and 10 lesions total. A sum of the LD for all target lesions was recorded. The use of a 20% increase in the sum of LD of target lesions from the smallest sum or appearance of a new lesion was assessed as progression of disease.
Time frame: From the screening visit of the first participant until the last evaluation of the final participant over 6 years later, assessed at the screening visit, end of cycle 2, end of each even cycle and during the final visit (end of treatment)
Tumor Progression in Expansion Cohort
Tumor progression evaluates changes in a tumor or tumors over time due to worsening of disease. Measurements and observations of the tumor status were performed before, during and after treatment. Tumor progression evaluates changes in a tumor or tumors over time due to worsening of disease. Measurements and observations of the tumor status were performed before, during and after treatment. Progression for solid tumors was evaluated based on the Response Evaluation Criteria in Solid Tumors (RECIST 1.0) criteria. Tumor dimensions were measured in millimeters and the longest diameter (LD) was recorded for up to 5 lesions per organ and 10 lesions total. A sum of the LD for all target lesions was recorded. The use of a 20% increase in the sum of LD of target lesions from the smallest sum or appearance of a new lesion was assessed as progression of disease.
Time frame: From the screening visit of the first participant until the last evaluation of the final participant over 6 years later, assessed at the screening visit, end of cycle 2, end of each even cycle and during the final visit (end of treatment)
Tumor Response in Dose Escalation Cohort
Tumor Response (= Best Overall Response) of a participant was defined as the best tumor response (Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD)) observed during trial period assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. CR was defined as disappearance of tumor lesions, PR was defined as a decrease of at least 30% in the sum of tumor lesion sizes, SD was defined as steady state of disease, PD was defined as an increase of at least 20% in the sum of tumor lesions sizes.
Time frame: From the screening visit of the first participant until the last evaluation of the final participant over 6 years later, assessed at the screening visit, end of cycle 2, end of each even cycle and during the final visit (end of treatment)
Tumor Response in Expansion Cohort
Tumor Response (= Best Overall Response) of a participant was defined as the best tumor response (Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD)) observed during trial period assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. CR was defined as disappearance of tumor lesions, PR was defined as a decrease of at least 30% in the sum of tumor lesion sizes, SD was defined as steady state of disease, PD was defined as an increase of at least 20% in the sum of tumor lesions sizes.
Time frame: From the screening visit of the first participant until the last evaluation of the final participant over 6 years later, assessed at the screening visit, end of cycle 2, end of each even cycle and during the final visit (end of treatment)
Adult participants with advanced, histologically or cytologically confirmed solid tumors (including non-small-cell lung cancer (NSCLC) participants enrolled in the expansion portion of the study), malignant lymphomas, or multiple myeloma were enrolled in 5 centers in the USA from 01 FEB 2007 to 22 Apr 2011.
| Milestone | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg | HCC Child-Pugh A Expansion Cohort: Regorafenib 100 mg | HCC Child-Pugh B Expansion Cohort: Regorafenib 100 mg | NSCLC Expansion Cohort: Regorafenib 100 mg |
|---|---|---|---|---|---|---|---|---|
| Started | 3 | 8 | 11 | 6 | 10 | 16 | 6 | 26 |
| Itt efficacy analysis population | 3 | 8 | 11 | 5 | 10 | 16 | 6 | 22 |
| Pk population | 3 | 8 | 10 | 6 | 10 | 14 | 6 | 24 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 8 | 11 | 6 | 10 | 16 | 6 | 26 |
| Withdrew: Adverse event | 0 | 2 | 4 | 0 | 2 | 0 | 0 | 2 |
| Withdrew: Disease progression, recurrence, relapse | 3 | 6 | 5 | 6 | 8 | 14 | 5 | 22 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 | 0 | 0 | 1 | 1 | 1 |
| Withdrew: Non-compliance with study medication | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Invest. text: completed all planned txs | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
The MTD was defined as the highest dose level, which could be given to 6 participants such that no more than 1 participant (less than 33%) experienced a dose-limiting toxicity (DLT).
| mg | Regorafenib, 20 mg, 40 mg, 100 mg, 120 mg, 140 mg |
|---|---|
| Maximum Tolerated Dose (MTD) | 100 |
Cmax refers to the highest measured drug concentration, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.
| mg/L | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg | HCC Child-Pugh A Expansion Cohort: Regorafenib 100 mg | HCC Child-Pugh B Expansion Cohort: Regorafenib 100 mg | NSCLC Expansion Cohort: Regorafenib 100 mg |
|---|---|---|---|---|---|---|---|---|
| Regorafenib (n=3,7,10,6,10,14,4,24) | 0.330 ± 14.8 | 0.422 ± 27.4 | 1.25 ± 30.7 | 1.87 ± 24.0 | 1.90 ± 51.2 | 1.38 ± 98 | 1.42 ± 76 | 1.25 ± 68.5 |
| M2 (BAY75-7495) (n=3,7,10,6,10,14,4,24) | 0.0181 ± 244 | 0.0867 ± 110 | 0.401 ± 51.2 | 0.645 ± 43.2 | 0.606 ± 97.2 | 0.42 ± 154 | 0.54 ± 129 | 0.388 ± 190 |
| M5 (BAY81-8752) (n=1,5,10,6,10,13,4,22) | 0.00290 ± NA | 0.00738 ± 124 | 0.0299 ± 118 | 0.0459 ± 59.2 | 0.0500 ± 140 | 0.036 ± 110 | 0.035 ± 352 | 0.321 ± 142 |
The AUC is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.
| mg*h/L | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg | HCC Child-Pugh A Expansion Cohort: Regorafenib 100 mg | HCC Child-Pugh B Expansion Cohort: Regorafenib 100 mg | NSCLC Expansion Cohort: Regorafenib 100 mg |
|---|---|---|---|---|---|---|---|---|
| Regorafenib (n=3,5,5,6,6,9,3,19) | NA ± NA | 16.3 ± 76.3 | 43.7 ± 34.9 | 52.9 ± 64.6 | 52.5 ± 66.4 | 45.2 ± 84.3 | 57.7 ± 30.9 | 33.5 ± 43.9 |
| M2 (BAY75-7495) (n=3,6,5,3,6,10,2,16) | NA ± NA | 3.53 ± 161 | 12.8 ± 37.0 | 21.0 ± 71.5 | 19.5 ± 20.3 | 15.3 ± 69.9 | 27.2 ± 74.6 | 11.6 ± 77.8 |
| M5 (BAY81-8752) (n=3,8,10,6,10,1,4,24) | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 15.8 ± NA | NA ± NA | NA ± NA |
Cmax,ss refers to the highest measured drug concentration, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample, after multiple dose administration and after a steady state concentration has been reached.
| mg/L | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg | HCC Child-Pugh A Expansion Cohort: Regorafenib 100 mg | HCC Child-Pugh B Expansion Cohort: Regorafenib 100 mg | NSCLC Expansion Cohort: Regorafenib 100 mg |
|---|---|---|---|---|---|---|---|---|
| Regorafenib (n=3,6,6,2,3,0,1,5) | 1.27 ± 19.4 | 1.50 ± 37.0 | 4.27 ± 22.9 | 3.62 ± 5.77 | 5.37 ± 30.9 | NA ± NA | 2.69 ± NA | 2.55 ± 92.4 |
| M2 (BAY75-7495) (n=3,6,6,2,3,0,1,5) | 0.0912 ± 39.5 | 0.520 ± 74.3 | 2.48 ± 36.3 | 2.97 ± 217 | 2.20 ± 106 | NA ± NA | 2.40 ± NA | 0.911 ± 126 |
| M5 (BAY81-8752) (n=3,6,6,2,3,0,1,5) | 0.00911 ± 15.7 | 0.174 ± 151 | 1.38 ± 87.0 | 3.29 ± 1400 | 0.948 ± 343 | NA ± NA | 1.59 ± NA | 0.349 ± 153 |
AUC(0-24),ss is a measure of systemic drug exposure over 24 hours, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample, after multiple dose administration and after a steady state concentration has been reached.
| mg*h/mL | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg | HCC Child-Pugh A Expansion Cohort: Regorafenib 100 mg | HCC Child-Pugh B Expansion Cohort: Regorafenib 100 mg | NSCLC Expansion Cohort: Regorafenib 100 mg |
|---|---|---|---|---|---|---|---|---|
| Regorafenib (n=3,6,6,2,3,0,1,5) | 12.9 ± 21.2 | 18.1 ± 35.9 | 49.6 ± 18.5 | 40.6 ± 32.9 | 60.4 ± 18.5 | NA ± NA | 39.2 ± NA | 35.8 ± 83.9 |
| M2 (BAY75-7495) (n=3,6,6,2,3,0,1,5) | 1.11 ± 42.9 | 7.20 ± 56.7 | 31.5 ± 25.2 | 40.9 ± 245 | 29.7 ± 88.8 | NA ± NA | 46.8 ± NA | 14.6 ± 104 |
| M5 (BAY81-8752) (n=3,6,6,2,3,0,1,5) | 0.122 ± 18.7 | 2.22 ± 136 | 18.6 ± 58.1 | 44.4 ± 3050 | 12.9 ± 231 | NA ± NA | 34.3 ± NA | 6.17 ± 133 |
The AUC(0-tlast) is a measure of systemic drug exposure from time 0 up to the time point at which the last measurable drug could be detectable, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.
| mg*h/L | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg | HCC Child-Pugh A Expansion Cohort: Regorafenib 100 mg | HCC Child-Pugh B Expansion Cohort: Regorafenib 100 mg | NSCLC Expansion Cohort: Regorafenib 100 mg |
|---|---|---|---|---|---|---|---|---|
| Regorafenib (n=3,7,10,6,10,14,4,24) | 7.98 ± 28.0 | 9.12 ± 38.8 | 32.7 ± 37.9 | 33.5 ± 60.4 | 35.8 ± 57.0 | 26.8 ± 67.5 | 33.0 ± 112 | 18.7 ± 55.3 |
| M2 (BAY75-7495) (n=3,7,10,6,10,14,4,24) | 0.384 ± 330 | 2.02 ± 108 | 11.3 ± 47.4 | 14.2 ± 53.4 | 13.6 ± 82.6 | 8.84 ± 122 | 13.4 ± 194 | 6.54 ± 156 |
| M5 (BAY81-8752) (n=1,5,10,6,10,13,4,22) | 0.0275 ± NA | 0.165 ± 254 | 0.976 ± 111 | 1.51 ± 71.1 | 1.54 ± 71.1 | 1.02 ± 122 | 0.821 ± 587 | 0.821 ± 254 |
The AUC/D is a measure of systemic drug exposure (AUC) after the first single dose, which is then divided by that dose. It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.
| h/L | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg | HCC Child-Pugh A Expansion Cohort: Regorafenib 100 mg | HCC Child-Pugh B Expansion Cohort: Regorafenib 100 mg | NSCLC Expansion Cohort: Regorafenib 100 mg |
|---|---|---|---|---|---|---|---|---|
| Regorafenib (n=3,5,5,6,6,9,3,19) | NA ± NA | 0.407 ± 76.3 | 0.437 ± 34.9 | 0.441 ± 64.6 | 0.375 ± 66.4 | 0.452 ± 84.3 | 0.577 ± 30.9 | 0.355 ± 43.9 |
| M2 (BAY75-7495) (n=3,6,5,3,6,10,2,16) | NA ± NA | 0.0855 ± 161 | 0.124 ± 37.0 | 0.169 ± 71.5 | 0.135 ± 20.3 | 0.148 ± 69.9 | 0.263 ± 74.6 | 0.113 ± 77.8 |
| M5 (BAY81-8752) (n=3,8,10,6,10,1,4,24) | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 0.0157 ± NA | NA ± NA | NA ± NA |
Cmax/D refers to the highest measured drug concentration after a single dose administration, which is then divided by the administered dose. It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.
| 1/L | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg | HCC Child-Pugh A Expansion Cohort: Regorafenib 100 mg | HCC Child-Pugh B Expansion Cohort: Regorafenib 100 mg | NSCLC Expansion Cohort: Regorafenib 100 mg |
|---|---|---|---|---|---|---|---|---|
| Regorafenib (n=3,7,10,6,10,14,4,24) | 0.0165 ± 14.8 | 0.0106 ± 27.4 | 0.0125 ± 30.7 | 0.0156 ± 24.0 | 0.0136 ± 51.2 | 0.0138 ± 97.9 | 0.0142 ± 76.1 | 0.0125 ± 68.5 |
| M2 (BAY75-7495) (n=3,7,10,6,10,14,4,24) | 0.000874 ± 244 | 0.00210 ± 110 | 0.00388 ± 51.2 | 0.00520 ± 43.2 | 0.00419 ± 97.2 | 0.00404 ± 154 | 0.00526 ± 129 | 0.00376 ± 190 |
| M5 (BAY81-8752) (n=1,5,10,6,10,13,4,22) | 0.000114 ± NA | 0.000184 ± 124 | 0.000298 ± 118 | 0.000381 ± 59.2 | 0.000355 ± 140 | 0.000355 ± 110 | 0.000351 ± 352 | 0.000320 ± 142 |
Tmax refers to the time after dosing when a drug attains its highest measurable concentration (Cmax). It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.
| h | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg | HCC Child-Pugh A Expansion Cohort: Regorafenib 100 mg | HCC Child-Pugh B Expansion Cohort: Regorafenib 100 mg | NSCLC Expansion Cohort: Regorafenib 100 mg |
|---|---|---|---|---|---|---|---|---|
| Regorafenib (n=3,8,10,6,10,14,4,24) | 8.00 (4.00 to 34.0) | 2.02 (2.00 to 10.0) | 5.00 (2.00 to 48.0) | 6.00 (2.00 to 24.0) | 3.01 (1.00 to 24.7) | 3.03 (2.00 to 24.0) | 3.00 (2.00 to 10.0) | 2.00 (1.00 to 48.1) |
| M2 (BAY75-7495) (n=3,8,10,6,10,14,4,24) | 8.00 (4.00 to 24.6) | 2.02 (2.00 to 10.0) | 10.0 (2.00 to 48.0) | 9.00 (2.00 to 24.0) | 4.00 (2.00 to 24.7) | 3.01 (2.00 to 24.0) | 10.0 (8.00 to 24.1) | 2.01 (2.00 to 48.0) |
| M5 (BAY81-8752) (n=1,5,10,6,10,13,4,22) | 48.0 (48.0 to 48.0) | 47.8 (10.0 to 48.0) | 48.0 (24.0 to 48.0) | 24.6 (10.0 to 48.0) | 47.6 (24.1 to 48.0) | 46.8 (4.00 to 48.6) | 34.9 (24.0 to 46.8) | 47.8 (4.00 to 48.4) |
T1/2 is the period of time required for the concentration or amount of drug in the body to be reduced to exactly one-half of a given concentration or amount. It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.
| h | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg | HCC Child-Pugh A Expansion Cohort: Regorafenib 100 mg | HCC Child-Pugh B Expansion Cohort: Regorafenib 100 mg | NSCLC Expansion Cohort: Regorafenib 100 mg |
|---|---|---|---|---|---|---|---|---|
| Regorafenib (n=3,5,5,3,6,9,22,19) | NA ± NA | 41.6 ± 41.1 | 31.6 ± 32.5 | 27.7 ± 47.8 | 23.2 ± 43.6 | 25.2 ± 52.0 | 745.3 ± 79.7 | 33.3 ± 64.8 |
| M2 (BAY75-7495) (n=3,6,5,3,6,10,2,16) | NA ± NA | 40.3 ± 52.3 | 24.8 ± 28.6 | 22.9 ± 27.6 | 22.7 ± 64.7 | 24.0 ± 56.3 | 19.2 ± 16.4 | 26.4 ± 73.4 |
| M5 (BAY81-8752) (n=3,8,10,6,10,1,4,24) | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 68.7 ± NA | NA ± NA | NA ± NA |
Cmax,ss/D refers to the highest measured drug concentration after multiple dose administration and after a steady state concentration has been reached, which is then divided by the administered dose. It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.
| 1/L | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg | HCC Child-Pugh A Expansion Cohort: Regorafenib 100 mg | HCC Child-Pugh B Expansion Cohort: Regorafenib 100 mg | NSCLC Expansion Cohort: Regorafenib 100 mg |
|---|---|---|---|---|---|---|---|---|
| Regorafenib (n=3,6,6,2,3,0,1,5) | 0.0636 ± 19.4 | 0.0374 ± 37.0 | 0.0427 ± 22.9 | 0.0302 ± 5.77 | 0.0383 ± 30.9 | NA ± NA | 0.0269 ± NA | 0.0255 ± 92.4 |
| M2 (BAY75-7495) (n=3,6,6,2,3,0,1,5) | 0.00441 ± 39.5 | 0.0126 ± 74.3 | 0.0241 ± 36.3 | 0.0240 ± 217 | 0.0152 ± 106 | NA ± NA | 0.0232 ± NA | 0.00881 ± 126 |
| M5 (BAY81-8752) (n=3,6,6,2,3,0,1,5) | 0.000454 ± 15.7 | 0.00434 ± 151 | 0.0137 ± 87.9 | 0.0273 ± 1400 | 0.00674 ± 343 | NA ± NA | 0.0159 ± NA | 0.00347 ± 153 |
AUC(0-24)ss/D is a measure of systemic drug exposure (AUC) over 24 hours after multiple dose administration and after a steady state concentration has been reached, which is then divided by the administered dose. It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.
| h/L | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg | HCC Child-Pugh A Expansion Cohort: Regorafenib 100 mg | HCC Child-Pugh B Expansion Cohort: Regorafenib 100 mg | NSCLC Expansion Cohort: Regorafenib 100 mg |
|---|---|---|---|---|---|---|---|---|
| Regorafenib (n=3,6,6,2,3,0,1,5) | 0.644 ± 21.2 | 0.452 ± 35.9 | 0.496 ± 18.5 | 0.338 ± 32.9 | 0.431 ± 18.5 | NA ± NA | 0.392 ± NA | 0.358 ± 83.8 |
| M2 (BAY75-7495) (n=3,6,6,2,3,0,1,5) | 0.0538 ± 42.9 | 0.174 ± 56.7 | 0.305 ± 25.2 | 0.330 ± 245 | 0.205 ± 88.8 | NA ± NA | 0.453 ± NA | 0.141 ± 104 |
| M5 (BAY81-8752) (n=3,6,6,2,3,0,1,5) | 0.00609 ± 18.7 | 0.0552 ± 136 | 0.185 ± 58.1 | 0.368 ± 3050 | 0.0916 ± 231 | NA ± NA | 0.342 ± NA | 0.0615 ± 133 |
Tmax,ss refers to the time after multiple dose administration and after a steady state concentration has been reached when a drug attains its highest measurable concentration (Cmax). It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.
| h | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg | HCC Child-Pugh A Expansion Cohort: Regorafenib 100 mg | HCC Child-Pugh B Expansion Cohort: Regorafenib 100 mg | NSCLC Expansion Cohort: Regorafenib 100 mg |
|---|---|---|---|---|---|---|---|---|
| Regorafenib (n=3,6,6,2,3,0,1,5) | 2.00 (2.00 to 4.00) | 2.00 (1.00 to 10.0) | 1.25 (0.00 to 4.00) | 2.00 (2.00 to 2.00) | 2.00 (1.00 to 4.00) | NA (NA to NA) | 4.03 (4.03 to 4.03) | 4.00 (2.00 to 10.0) |
| M2 (BAY75-7495) (n=3,6,6,2,3,0,1,5) | 2.00 (2.00 to 4.00) | 1.50 (1.00 to 10.0) | 2.00 (0.00 to 8.00) | 2.00 (2.00 to 2.00) | 2.00 (1.00 to 8.00) | NA (NA to NA) | 10.0 (10.0 to 10.0) | 4.00 (2.00 to 10.0) |
| M5 (BAY81-8752) (n=3,6,6,2,3,0,1,5) | 2.00 (0.500 to 4.00) | 1.00 (1.00 to 1.00) | 1.00 (0.00 to 24.0) | 1.50 (1.00 to 2.00) | 1.00 (0.00 to 8.00) | NA (NA to NA) | 0.00 (0.00 to 0.00) | 4.00 (0.00 to 10.0) |
RACmax is the ratio of the highest drug concentration at steady state to the highest drug concentration after single dose administration. It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.
| Ratio | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg | HCC Child-Pugh A Expansion Cohort: Regorafenib 100 mg | HCC Child-Pugh B Expansion Cohort: Regorafenib 100 mg | NSCLC Expansion Cohort: Regorafenib 100 mg |
|---|---|---|---|---|---|---|---|---|
| Regorafenib (n=3,5,6,2,3,0,1,5) | 3.78 | 3.34 | 3.50 | 1.53 | 2.84 | NA | 1.90 | 1.82 |
| M2 (BAY75-7495) (n=3,5,6,2,3,0,1,5) | 4.86 | 4.26 | 5.39 | 3.06 | 3.33 | NA | 3.40 | 1.83 |
| M5 (BAY81-8752) (n=1,4,6,2,3,0,1,5) | 3.80 | 22.8 | 32.5 | 39.3 | 18.9 | NA | 45.0 | 11.9 |
RACmin is the ratio of the lowest drug concentration at steady state to the lowest drug concentration after single dose administration. It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.
| Ratio | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg | HCC Child-Pugh A Expansion Cohort: Regorafenib 100 mg | HCC Child-Pugh B Expansion Cohort: Regorafenib 100 mg | NSCLC Expansion Cohort: Regorafenib 100 mg |
|---|---|---|---|---|---|---|---|---|
| Regorafenib (n=3,6,6,2,3,0,1,5) | 4.82 | 34.9 | 26.1 | 413 | 10.9 | NA | 7.80 | 14.1 |
| M2 (BAY75-7495) (n=3,6,6,2,3,0,1,5) | 4.81 | 10.4 | 24.2 | 12.6 | 3.33 | NA | 103 | 11.5 |
| M5 (BAY81-8752) (n=0,4,,6,2,3,0,1,5) | NA | 26.1 | 102 | 335 | 46.2 | NA | 257 | 22.4 |
RAAUC is the ratio of the measure of systemic drug exposure over a specific dosing interval at steady state to the measure of systemic drug exposure over a specific dosing interval after single dose administration. It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.
| Ratio | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg | HCC Child-Pugh A Expansion Cohort: Regorafenib 100 mg | HCC Child-Pugh B Expansion Cohort: Regorafenib 100 mg | NSCLC Expansion Cohort: Regorafenib 100 mg |
|---|---|---|---|---|---|---|---|---|
| Regorafenib (n=3,5,6,2,3,0,1,5) | 3.20 | 3.78 | 3.15 | 1.37 | 3.61 | NA | 2.10 | 2.67 |
| M2 (BAY75-7495) (n=3,5,6,2,3,0,1,5) | 5.79 | 4.72 | 4.63 | 2.71 | 3.60 | NA | 4.60 | 2.74 |
| M5 (BAY81-8752) (n=0,4,,6,2,3,0,1,5) | NA | 28.1 | 41.2 | 34.7 | 23.9 | NA | 63.0 | 18.5 |
RLIN is the ratio of the measure of systemic drug exposure at steady state to the measure of systemic drug exposure after single dose administration. It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.
| Ratio | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg | HCC Child-Pugh A Expansion Cohort: Regorafenib 100 mg | HCC Child-Pugh B Expansion Cohort: Regorafenib 100 mg | NSCLC Expansion Cohort: Regorafenib 100 mg |
|---|---|---|---|---|---|---|---|---|
| Regorafenib (n=0,3,3,2,3,0,1,4) | NA | 1.53 | 1.27 | 0.600 | 2.20 | NA | 0.800 | 1.11 |
| M2 (BAY75-7495) (n=0,4,3,0,2,0,1,4) | NA | 1.63 | 2.13 | NA | 1.39 | NA | 2.70 | 1.27 |
| M5 (BAY81-8752) (n=0) | NA | NA | NA | NA | NA | NA | NA | NA |
The analysis of Biomarker VEGF plasma levels is not done
No measurements were reported for this outcome.
The analysis of Biomarker sCEGFR-2 plasma levels is not done.
No measurements were reported for this outcome.
Tumor progression evaluates changes in a tumor or tumors over time due to worsening of disease. Measurements and observations of the tumor status were performed before, during and after treatment. Progression for solid tumors was evaluated based on the Response Evaluation Criteria in Solid Tumors (RECIST 1.0) criteria. Tumor dimensions were measured in millimeters and the longest diameter (LD) was recorded for up to 5 lesions per organ and 10 lesions total. A sum of the LD for all target lesions was recorded. The use of a 20% increase in the sum of LD of target lesions from the smallest sum or appearance of a new lesion was assessed as progression of disease.
| Participants | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg |
|---|---|---|---|---|---|
| Participants without progression | 1 | 3 | 9 | 2 | 5 |
| Participants with progression | 2 | 5 | 2 | 3 | 5 |
Tumor progression evaluates changes in a tumor or tumors over time due to worsening of disease. Measurements and observations of the tumor status were performed before, during and after treatment. Tumor progression evaluates changes in a tumor or tumors over time due to worsening of disease. Measurements and observations of the tumor status were performed before, during and after treatment. Progression for solid tumors was evaluated based on the Response Evaluation Criteria in Solid Tumors (RECIST 1.0) criteria. Tumor dimensions were measured in millimeters and the longest diameter (LD) was recorded for up to 5 lesions per organ and 10 lesions total. A sum of the LD for all target lesions was recorded. The use of a 20% increase in the sum of LD of target lesions from the smallest sum or appearance of a new lesion was assessed as progression of disease.
| Participants | HCC Expansion Cohort: Regorafenib 100 mg | NSCLC Expansion Cohort: Regorafenib 100 mg |
|---|---|---|
| Participants without progression | 10 | 6 |
| Participants with progression | 12 | 16 |
Tumor Response (= Best Overall Response) of a participant was defined as the best tumor response (Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD)) observed during trial period assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. CR was defined as disappearance of tumor lesions, PR was defined as a decrease of at least 30% in the sum of tumor lesion sizes, SD was defined as steady state of disease, PD was defined as an increase of at least 20% in the sum of tumor lesions sizes.
| Participants | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg |
|---|---|---|---|---|---|
| Not assessable | 0 | 1 | 2 | 0 | 0 |
| Partial Response (PR) | 0 | 0 | 2 | 0 | 1 |
| Stable Disease (SD) | 1 | 2 | 5 | 2 | 4 |
| Progressive Disease (PD) | 2 | 4 | 2 | 2 | 4 |
| Progression | 0 | 1 | 0 | 1 | 1 |
Tumor Response (= Best Overall Response) of a participant was defined as the best tumor response (Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD)) observed during trial period assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. CR was defined as disappearance of tumor lesions, PR was defined as a decrease of at least 30% in the sum of tumor lesion sizes, SD was defined as steady state of disease, PD was defined as an increase of at least 20% in the sum of tumor lesions sizes.
| Participants | HCC Expansion Cohort, Regorafenib 100 mg | NSCLC Expansion Cohort, Regorafenib 100 mg |
|---|---|---|
| Not assessable | 3 | 1 |
| Partial Response (PR) | 1 | 0 |
| Stable Disease (SD) | 6 | 5 |
| Progressive Disease (PD) | 10 | 12 |
| Progression | 2 | 4 |
Collected over Adverse events were collected after signing the informed consent of the first participant until the end of study completion for the last patient, therefore for the study over a period of approximately 6 years and 9 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg | — | 0/3 (0%) | 2/3 (66.7%) |
| Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg | — | 3/8 (37.5%) | 8/8 (100%) |
| Regorafenib (Stivarga, BAY73-4506) 100 mg | — | 31/59 (52.5%) | 58/59 (98.3%) |
| Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg | — | 3/6 (50%) | 5/6 (83.3%) |
| Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg | — | 6/10 (60%) | 10/10 (100%) |
| Event | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg | Regorafenib (Stivarga, BAY73-4506) 100 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg |
|---|---|---|---|---|---|
| Cardiac General - OtherCardiac disorders | 0/3 | 0/8 | 3/59 | 0/6 | 2/10 |
| SupraVentricular arrhythmia, Sinus tachycardiaCardiac disorders | 0/3 | 0/8 | 0/59 | 1/6 | 0/10 |
| Blurred visionEye disorders | 0/3 | 0/8 | 0/59 | 1/6 | 0/10 |
| Ocular - OtherEye disorders | 0/3 | 0/8 | 1/59 | 1/6 | 0/10 |
| FatigueGeneral disorders | 0/3 | 0/8 | 4/59 | 1/6 | 0/10 |
| Pain, Chest/thorax NOSGeneral disorders | 0/3 | 1/8 | 0/59 | 1/6 | 0/10 |
| Infection (Documented clinically), Lung (pneumonia)Infections and infestations | 0/3 | 0/8 | 4/59 | 1/6 | 0/10 |
| Dyspnea (shortness of breath)Respiratory, thoracic and mediastinal disorders | 0/3 | 1/8 | 1/59 | 1/6 | 0/10 |
| Obstruction, GI, DuodenumGastrointestinal disorders | 0/3 | 1/8 | 0/59 | 0/6 | 0/10 |
| FractureMusculoskeletal and connective tissue disorders | 0/3 | 1/8 | 0/59 | 0/6 | 0/10 |
| Event | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg | Regorafenib (Stivarga, BAY73-4506) 100 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg |
|---|---|---|---|---|---|
| Rash/desquamationSkin and subcutaneous tissue disorders | 1/3 | 6/8 | 19/59 | 5/6 | 9/10 |
| Pain, Extremity - limbGeneral disorders | 0/3 | 0/8 | 15/59 | 5/6 | 5/10 |
| DiarrheaGastrointestinal disorders | 2/3 | 2/8 | 15/59 | 2/6 | 4/10 |
| FatigueGeneral disorders | 2/3 | 5/8 | 28/59 | 4/6 | 5/10 |
| Pain, BackGeneral disorders | 0/3 | 1/8 | 13/59 | 4/6 | 2/10 |
| Pain, MuscleGeneral disorders | 0/3 | 0/8 | 10/59 | 4/6 | 3/10 |
| ConstipationGastrointestinal disorders | 0/3 | 2/8 | 14/59 | 3/6 | 3/10 |
| Mucositis (functional/symptomatic), Oral cavityGastrointestinal disorders | 0/3 | 0/8 | 11/59 | 3/6 | 4/10 |
| Bilirubin (hyperbilirubinemia)Metabolism and nutrition disorders | 0/3 | 0/8 | 7/59 | 0/6 | 5/10 |
| InsomniaGeneral disorders | 0/3 | 1/8 | 11/59 | 0/6 | 4/10 |
| Age, Continuous(Years) | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg | HCC Child-Pugh A Expansion Cohort: Regorafenib 100 mg | HCC Child-Pugh B Expansion Cohort: Regorafenib 100 mg | NSCLC Expansion Cohort: Regorafenib 100 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 63.3 ± 8.1 | 55.3 ± 13.1 | 61.9 ± 8.8 | 59.2 ± 10.7 | 55.7 ± 13.7 | 56.6 ± 13.2 | 56.7 ± 13.1 | 62.4 ± 12.2 | 59.6 ± 11.8 |
| Sex: Female, Male(Participants) | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg | Escalation Cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg | HCC Child-Pugh A Expansion Cohort: Regorafenib 100 mg | HCC Child-Pugh B Expansion Cohort: Regorafenib 100 mg | NSCLC Expansion Cohort: Regorafenib 100 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 3 | 4 | 3 | 7 | 4 | 2 | 9 | 32 |
| Male | 3 | 5 | 7 | 3 | 3 | 12 | 4 | 17 | 54 |
The record gives a start of Feb 2007, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2015, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Regorafenib